General Statement of Disclosure:

CONSULTING FEES/HONORARIA: Protalix(MODEST), Abbott Laboratories(SIGNIFICANT), Sanofi Genzyme(SIGNIFICANT), Amicus(MODEST), Medtronic(SIGNIFICANT), Bayer Healthcare Pharmaceuticals(SIGNIFICANT), Chiesi(MODEST), Stealth Biotherapeutics(SIGNIFICANT), Novartis(NONE), Nuwellis(SIGNIFICANT), Alnylam(MODEST), Bristol Myers Squibb(MODEST), Daxor(SIGNIFICANT), Boehringer Ingelheim Pharmaceuticals, Inc(MODEST), Sangamo(MODEST), Freeline(MODEST), Tenaya(MODEST), Cytokinetics(MODEST) SPEAKER'S BUREAU: Sanofi Genzyme(SIGNIFICANT), Pfizer Inc(MODEST), Ambry Genetics(MODEST), NS Pharma(MODEST) EQUITY INTERESTS/STOCK OPTIONS: Nuwellis(SIGNIFICANT), Daxor(SIGNIFICANT) OWNERSHIP/PARTNERSHIP/PRINCIPAL: Yendii(NONE) RESEARCH/RESEARCH GRANTS: Pfizer(SIGNIFICANT), Myokardia(SIGNIFICANT), Biocardia(SIGNIFICANT), Veru(SIGNIFICANT), HeartBeam(SIGNIFICANT), Innolife(SIGNIFICANT), V Wave(SIGNIFICANT)

View Full Disclosure